T cell responses generated by HIV vaccines in clinical trials

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 375-379

  De Rosa, Stephen D ^a   McElrath, M Juliana ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

ELISpot; HIV vaccine; Intracellular cytokine staining; T cell immunogenicity

Indexed keywords

ADENOVIRUS VECTOR; CANARYPOX VACCINE; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NEFTAT PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE; PLACEBO; POL PROTEIN; REAGENT; RECOMBINANT DNA; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS VACCINE;

ADENOVIRUS; ANTIBODY RESPONSE; ANTIBODY TITER; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOPRESERVATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE INSERTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SEROTYPE; STANDARDIZATION; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VALIDATION PROCESS; VEIN PUNCTURE; VIRUS GENE; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 42049083555     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fbaaa7     Document Type: Review

References (22)

1. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007; 322:57-69.
2. Kierstead LS, Dubey S, Meyer B, et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 2007; 23:86-92.
3. Dubey S, Clair J, Fu TM, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007; 45:20-27.
4. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54.
5. Malhotra U, Li F, Nolin J, et al. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol 2007; 81:5225-5237.
6. Frahm N, Kaufmann DE, Yusim K, et al. Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol 2007; 179:6638-6650.
7. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
8. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204:1405-1416.
9. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203-212.
10. Cleghorn F, Pape JW, Schechter M, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 2007; 46:222-230.
11. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48-55.
12. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-518.
13. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649.
14. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-4092.
15. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-1660.
16. Cohen J. AIDS research, Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318:28-29.
17. Cohen J. AIDS research, Did Merck's failed HIV vaccine cause harm? Science 2007; 318:1048-1049.
18. Cohen J, Lester B. AIDS research, Trials of NIH's AIDS vaccine get a yellow light. Science 2007; 318:1852.
19. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
20. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555.
21. Casimiro DR, Bett AJ, Fu TM, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004; 78:11434-11438.
22. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305-6313.